---
title: "阿斯利康：巴昔多司他在 BaxHTN III 期试验中达到主要终点和所有次要终点。 巴昔 多司他 2 毫克剂量使收缩压较基线水平降低了 15.7 毫米汞柱。 巴昔多司他总体耐受性良好，未发现意料之外的"
description: "阿斯利康：巴昔多司他在 BaxHTN III 期试验中达到主要终点和所有次要终点。 巴昔 多司他 2 毫克剂量使收缩压较基线水平降低了 15.7 毫米汞柱。 巴昔多司他总体耐受性良好，未发现意料之外的安全问题。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255314987.md"
published_at: "2025-08-30T14:17:10.000Z"
---

# 阿斯利康：巴昔多司他在 BaxHTN III 期试验中达到主要终点和所有次要终点。 巴昔 多司他 2 毫克剂量使收缩压较基线水平降低了 15.7 毫米汞柱。 巴昔多司他总体耐受性良好，未发现意料之外的

> 阿斯利康：巴昔多司他在 BaxHTN III 期试验中达到主要终点和所有次要终点。 巴昔 多司他 2 毫克剂量使收缩压较基线水平降低了 15.7 毫米汞柱。 巴昔多司他总体耐受性良好，未发现意料之外的安全问题。

阿斯利康：巴昔多司他在 BaxHTN III 期试验中达到主要终点和所有次要终点。 巴昔 多司他 2 毫克剂量使收缩压较基线水平降低了 15.7 毫米汞柱。 巴昔多司他总体耐受性良好，未发现意料之外的安全问题。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-CN/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/zh-CN/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/zh-CN/news/259563996.md) |
| Advance Auto Parts’ Heavy Debt Load Raises Liquidity, Refinancing and Turnaround Risks | Advance Auto Parts Inc (AAP) is facing significant financial risks due to its heavy debt load, which may limit liquidity | [Link](https://longbridge.com/zh-CN/news/275997122.md) |
| Ibn Al Haytham Hospital FY Income 301,281 Dinars | Ibn Al Haytham Hospital Company PSC (IBNH.AM):IBN AL HAYTHAM HOSPITAL FY NET INCOME AFTER TAX 301,281 DINARSIBN AL HAYTH | [Link](https://longbridge.com/zh-CN/news/275996849.md) |
| Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/zh-CN/news/275995095.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。